|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Factors with remission of fatty liver in patients With type 2 diabetes treated with ipragliflozin
| Title: | Factors with remission of fatty liver in patients With type 2 diabetes treated with ipragliflozin |
| Authors: | Yamauchi, Yuki Browse this author | | Nakamura, Akinobu Browse this author →KAKEN DB | | Takahashi, Kiyohiko Browse this author | | Takase, Takahiro Browse this author | | Yamamoto, Chiho Browse this author | | Yokota, Isao Browse this author →KAKEN DB | | Atsumi, Tatsuya Browse this author →KAKEN DB | | Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | Fatty liver | | Ipragliflozin | | Diabetes |
| Issue Date: | 2019 |
| Publisher: | The Japan Endocrine Society |
| Journal Title: | Endocrine journal |
| Volume: | 66 |
| Issue: | 11 |
| Start Page: | 995 |
| End Page: | 1000 |
| Publisher DOI: | 10.1507/endocrj.EJ19-0136 |
| Abstract: | We investigated the factors associated with fatty liver remission via treatment with ipraglitlozin. The analysis was obtained from our multi-center prospective observational study, including 200 Japanese patients with type 2 diabetes treated with ipragliflozin (50 mg/day) for 24 weeks. The extent of fatty liver was estimated using a fatty liver index (FLI). Based on the FLI after the treatment with ipragliflozin, patients were classified into remission group (FLI < 30) and non-remission group (FLI >= 30). After treatment with ipragliflozin for 24 weeks, FLI significantly improved from 64.5 +/- 21.6 to 51.9 +/- 26.5 (p < 0.01). Body weight, body mass index, waist circumference, aspartate aminotransferase, alanine aminotransferase, and FLI in the remission group were significantly lower compared with those of the non-remission group. Stepwise analysis showed that the baseline FLI (Odds ratio 0.86; 95% confidence interval 0.81-0.90, p < 0.01) was an independent factor associated with FLI remission. Using a receiver operating characteristic (ROC) analysis, the adequate cut-off value for the remission was 50. The area under the ROC curve was 0.93 with the sensitivity and specificity 84.6% and 90.1% respectively. In conclusion, ipragliflozin ameliorated fatty liver. These results suggest that patients with fatty liver with a lower FLI are more likely to attain remission by the treatment with ipraglitlozin. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/76513 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
